Products & Services · Deferred Revenue
Research Services Obligation — Deferred Revenue
Alnylam Pharmaceuticals Research Services Obligation — Deferred Revenue decreased by 33.3% to $3.2M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 88.3%, from $27.3M to $3.2M. Over 4 years (FY 2021 to FY 2025), Research Services Obligation — Deferred Revenue shows a downward trend with a -27.1% CAGR.
Analysis
Metric ID:
alny_segment_research_services_obligation_deferred_revenueHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $47.4M | $41M | $42.3M | $40.1M | $38.5M | $33.2M | $26.2M | $23M | $45M | $72M | $63.4M | $48.7M | $41.47M | $45.47M | $41.16M | $27.3M | $15.08M | $2.54M | $4.8M | $3.2M |
| QoQ Change | — | -13.5% | +3.2% | -5.2% | -4.0% | -13.8% | -21.1% | -12.2% | +95.7% | +60.0% | -11.9% | -23.2% | -14.8% | +9.7% | -9.5% | -33.7% | -44.8% | -83.1% | +88.9% | -33.3% |
| YoY Change | — | — | — | — | -18.8% | -19.0% | -38.1% | -42.6% | +16.9% | +116.9% | +142.0% | +111.7% | -7.8% | -36.8% | -35.1% | -43.9% | -63.6% | -94.4% | -88.3% | -88.3% |
Range$2.54M – $72M
CAGR-43.3%
Avg YoY Growth-11.8%
Median YoY Growth-36.0%
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's research services obligation — deferred revenue?
- Alnylam Pharmaceuticals (ALNY) reported research services obligation — deferred revenue of $3.2M in Q1 2026.
- How has Alnylam Pharmaceuticals's research services obligation — deferred revenue changed year-over-year?
- Alnylam Pharmaceuticals's research services obligation — deferred revenue decreased by 88.3% year-over-year, from $27.3M to $3.2M.
- What is the long-term trend for Alnylam Pharmaceuticals's research services obligation — deferred revenue?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's research services obligation — deferred revenue has grown at a -27.1% compound annual growth rate (CAGR), from $175.8M to $49.72M.